MOLECULAR-GENETIC «PORTRAIT» OF BREAST CANCER
https://doi.org/10.24884/1607-4181-2017-24-2-12-22
Abstract
Understanding genetic mechanisms and detection of biological markers of tumor growth forms an individual molecular phenotype of
transformed cells that characterizes stage of tumor, the ability to metastasize, hormonal sensitivity, chemotherapyefficiencyetc. Mutations in proto- and anti-oncogenes controlling mitotic activity of cells and their ability to DNA reparation are often found in tumor cells in patients with cancer. Defects of classical tumor suppressor genes (BRCA1/2, CHEK2, ATM, PALB2, NBS1, TP53, etc.) determine the hereditary predisposition to breast cancer caused by genomic instability and appearance of «chimeric» genes, aneuploidies and chromosomal aberrations. Breast cancer is a genetically heterogeneous disease with various molecular, biological and clinical features. Identificationof the molecular phenotype of breast carcinomas is an important prognostic factor of the disease, and it helps to individualize the therapeutic approach for patients.
About the Authors
S. A. Laptiev
Federal State Budgetary Educational Institution of Higher Education «Academician I. P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of the Russion Federation
Russian Federation
6-8 L’va Tolstogo street, Saint-Petersburg, Russia, 197022
Competing Interests: Конфликт интересов отсутствует
Russian Federation
6-8 L’va Tolstogo street, Saint-Petersburg, Russia, 197022
Competing Interests: Конфликт интересов отсутствует
M. A. Korzhenevskaia
Federal State Budgetary Educational Institution of Higher Education «Academician I. P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of the Russion Federation
Russian Federation
Competing Interests: Конфликт интересов отсутствует
Russian Federation
Competing Interests: Конфликт интересов отсутствует
E. N. Imyanitov
FSBI «N. N. Petrov Institute of Oncology» Ministry of Health of the Russian Federation
Russian Federation
Competing Interests: Конфликт интересов отсутствует
Russian Federation
Competing Interests: Конфликт интересов отсутствует
References
1. Kaprin A.D., Starinskyi V.V., Petrova G.V. Malignant tumors in Russia in 2015 year (morbidity and mortality). M., «P. Herzen Moscow Oncology Research Institute» - branch of the FSBI «National Medical Research Radiological Center» of the Ministry of Health of the Russian Federation. 2017; 250 pp. (in Russ.)
2. Lyubchenko L.N., Bateneva E.I. Medical genetic counseling and DNA testing when hereditary predisposition to breast and ovarian cancer. M., FSBI «Russian Cancer Research Center named after N.N. Blokhin» of the Russian Ministry of Health. 2014; 75 pp. (in Russ.)
3. Semiglazov V.F., Semiglazov V.V. Genetic screening in breast cancer. Pract oncol. 2010; 11(2): 60-65. (in Russ.)
4. Turnpenny P., Ellard S. Emery’s elements of human genetics. UK, Elsevier. 2009; 13: 196-212.
5. Gonzalez-Reymundez A. et al. Prediction of years of life after diagnosis of breast cancer using OMICs and OMIC-bytretment interactions. Europ J Hum Genet. 2017; 25: 538-544.
6. Semiglazov V.F. et al. Neoadjuvant targeted therapy for breast cancer. Effectiv Pharmacother. 2013; 6: 12-16. (in Russ.)
7. Semiglazov V.F. Breast cancer: multidisciplinary approach to treatment. Pract oncol. 2015; 16(2): 49-54. (in Russ.)
8. Korzhenevskaya M.A., Gorbunova V.N. et al. Genetics in clinical practice. SPb., «SpetsLit». 2015; 293-305. (in Russ.)
9. Alberts B. et al. Molecular biology of the cell. NY, Garland Sci. 2012; 5: 1205-1268.
10. Zaridze D.G. Cancerogenesis. M., «Medicine». 2004; 576 pp. (in Russ.)
11. Toporova N.E. et al. Molecular genetic studies in the practice of oncological clinic. Izvest Samara Sc Cen Rus Acad Sc. 2015; 17(3): 690-696. (in Russ.)
12. Guarnerio J. et al. Oncogenic role of fusion -circRNAs derived from cancer- associated chromosomal translocations. Cell. 2016; 165(2): 289-302.
13. Imyanitov E.N. Fundamental oncology in 2016 year: a review of the most interesting discoveries. Pract oncol. 2017; 18 (1): 85-92. (in Russ.)
14. Marchio C, Reis-Filho J.S. Molecular diagnosis in breast cancer. Diagnostic histopathol. 2008; 15(4): 202-213.
15. Imyanitov E.N. General ideas about targeted therapy. Pract oncol. 2010; 3: 123-130. (in Russ.)
16. Semiglazov V.F. Strategy and practical approaches to solve the problem of breast cancer. Oncol Iss. 2012; 58(2): 148-152. (in Russ.)
17. Tyulyandin S.A. et al. Minimal clinical reccomendations of the ESMO. M., FSBI «Russian Cancer Research Center named after N.N. Blokhin» of the Russian Ministry of Health. 2010; 8-27. (in Russ.)
18. Perevodchikova N.I., Stenina M.B. et al. Hormontherapy in breast cancer. M. 2010; 71 pp. (in Russ.)
19. Semiglazov V.F., Semiglazov V.V., Dashyan G.A. Endocrinotherapy of early breast cancer. M., «MEDpress-inform». 2011; 96 pp. (in Russ.)
20. Chumakov P.M. P53 protein and its universal functions in multicellular organism. Advan Biol Chemistr. 2007; 47: 3-52. (in Russ.)
21. Mayboroda A.A. Molecular genetic basis of oncogenesis. Siberian Med J. 2013; 116 (1): 134-138. (in Russ.)
22. Lyubchenko L.N. et al. Hereditary breast and ovarian cancer. J Malign Tum. 2013; 53-61. (in Russ.)
23. Ergul E., Sazci A. Molecular genetics of breast cancer. Turk J Med Sci. 2001; 31: 1-14.
24. Groep P. et al. Pathology of hereditary breast cancer. Cell Oncol. 2011; 34: 71-88.
25. Sokolenko A.P., Iyevleva A.G., Imyanitov E.N. What do you need to know about hereditary breast and ovarian cancer. SPb., SBEI of Higher Professional Education «North-Western Medical University named after I.I. Mechnikov» of the Ministry of Health of the Russian Federation. 2016; 46 pp. (in Russ.)
26. Knudson A. et al. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971; 68(4): 820–823.
27. Knudson A. et al. Two genetics hits (more or less) to cancer. Nature Rev Can. 2001; 1: 157-162.
28. Imyanitov E.N. Screening in persons with hereditary predisposition to cancer. Pract oncol. 2011; 2: 102-109. (in Russ.)
29. Liedtke C. et al. Genomic profiling in triple-negative breast cancer. Br Care (Basel). 2013; 8(6): 408-413.
30. Narod S.A., Foulkes W.D. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Can. 2004; 4: 665-676.
31. Byrski T. et al., Pathologic complete response rates in young women with BRCA-1 positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010; 28: 375-379.
32. Iyevleva A.G., Imyanitov E.N. Cytotoxic and targeted therapy for hereditary cancers. Hered Can Clin Pract. 2016; 14(1): 1-17.
33. Moiseyenko V. M. et al., High sensitivity of BRCA1 associated tumors to cisplatin monotherapy: report of two cases. Cancer Genet Cytogenet. 2010; 197: 91-94.
34. Imyanitov E.N. Principles of individualization of anticancer therapy. Pract oncol. 2013; 14(4): 187-194. (in Russ.)
35. Braso-Maristany F. et al. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nature. 2016; 539(7627): 107-111.
36. Nolan E. et al. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med. 2016; 22(8): 933-939.
37. Nolan E. et al. Out-RANKing BRCA1 in mutation carriers. Can Res. 2017; 77(3): 595-600.
Supplementary files
|
|
1. Рисунок 1. Генетический контроль клеточного цикла | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(216KB)
|
Indexing metadata ▾ | |
|
|
2. Рисунок 2. Мутации в протоонкогенах и антионкогенах | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(647KB)
|
Indexing metadata ▾ | |
|
|
3. Рисунок 3. Наследственный и ненаследственный рак | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(629KB)
|
Indexing metadata ▾ | |
|
|
4. Сопроводительное письмо | |
| Subject | ||
| Type | Other | |
View
(447KB)
|
Indexing metadata ▾ | |
|
|
5. Сопроводительное письмо | |
| Subject | ||
| Type | Other | |
View
(501KB)
|
Indexing metadata ▾ | |
Review
For citations:
Laptiev S.A., Korzhenevskaia M.A., Imyanitov E.N. MOLECULAR-GENETIC «PORTRAIT» OF BREAST CANCER. The Scientific Notes of the Pavlov University. 2017;24(2):12-22. (In Russ.) https://doi.org/10.24884/1607-4181-2017-24-2-12-22
Views:
1778
Email this article 